The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Immune-based therapies, such as therapeutic vaccination, that might preserve, restore, enhance and induce new HIV-specific immunologic responses are currently being explored. HIV-specific immunotherapy with Remune (The Immune Response Corp.) offers the opportunity to boost immune responses against HIV-1. The clinical trial program in a wide range of subjects has established the efficacy of Remune in stimulating an appropriate immune response in HIV-positive individuals. Furthermore, a recent unblinded study conducted in Europe has documented a significant effect of Remune on viral load. Evidence regarding clinical end points is more difficult to collect. The same studies have revealed no serious safety issues in a total of more than 2000 Remune-treated patients. It is therefore reasonable to suggest that the risk-benefit ratio of Remune could be positive.
Fernández-Cruz
Eduardo
E
University General Hospital Gregorio Marañón, Immunology Department, Complutense University of Madrid, Madrid, Spain. efernandez@inmuno.hggm.es
Navarro
Joaquín
J
Rodríguez-Sainz
Carmen
C
Gil
Juana
J
Moreno
Santiago
S
González-Lahoz
Juan
J
Carbone
Javier
J
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018570:Risk Assessment; D014611:Vaccination / Q000009:adverse effects
D016915:AIDS Vaccines; C105086:remune